Focus: Actio Biosciences is a San Diego-based biotech company founded in 2010 focused on genetics-based therapeutics for oncology and rare diseases. The company operates as a publicly traded entity with a specialized genetics platform.
Profile data last refreshed 12h ago · AI intelligence enriched 3d ago
No open roles listed right now. Follow Actio Biosciences to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Actio Biosciences
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Actio Biosciences's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
8-K Filing: Eloxx Pharmaceuticals, Inc. (ELOX) (CIK 0001035354) — 8-K
8-K
FDA Finalizes Food Chemical Safety Post-Market Assessment Program, Launches Reassessment of BHT, ADA
FDA continues to implement its bold food agenda, with two decisive actions focused on food chemical safety.
Actio Biosciences begins trial of ABS-1230 for epilepsy - Clinical Trials Arena
Actio Biosciences begins trial of ABS-1230 for epilepsy Clinical Trials Arena
No open positions listed yet. Check their careers page directly.
Recent peer-reviewed publications with author affiliations at this company
Showing 5 of 9 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo